Johnson & Johnson Cardiac Trial Data Refines Impella Role In MedTech Story [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Johnson & Johnson (NYSE:JNJ) reported results from the randomized STEMI DTU trial of its Impella CP device at ACC 2026. The study assessed use of Impella CP before coronary intervention in heart attack patients. Findings showed no reduction in heart muscle damage, but offered practice-informing data for acute cardiac care. The results are expected to guide future research on device use and potential adjunct pharmacotherapies. For Johnson & Johnson, cardiac devices sit within a broad MedTech portfolio that complements its pharmaceutical and consumer health heritage. The STEMI DTU data provides new information on how one of its heart support technologies performs in a controlled clinical setting, adding clinical detail that sits alongside attention on immunology and oncology activities. While the trial results are neutral on heart muscle damage, they help clarify where Impella CP may fit in real world practice and where it might not. For investors, this type of data can infor
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson (JNJ) had its price target raised by Morgan Stanley from $262.00 to $267.00. They now have an "overweight" rating on the stock.MarketBeat
- Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of VisionBusiness Wire
- Johnson & Johnson PFA Launch Puts VARIPULSE Pro And Valuation In Focus [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know [Yahoo! Finance]Yahoo! Finance
- How Raw Sugar Living's CEO Is Fighting Inflation In The Beauty Aisle [Forbes]Forbes
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- JNJ's page on the SEC website